Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Is looking” - so in other words, they aren’t doing this currently.
Elite has pivoted to primarily a GENERIC manufacturing company and has no marketed products being sold that would be based on patents Elite holds. If anything, this could potentially even help Elite if it happens.
“The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, **to take patents for drugs developed with taxpayer funds and share them with other pharmaceutical companies** if the public cannot ‘reasonably’ access the medications.”
Oh, share them with other companies? Like, generic manufacturers? Like possibly Elite? LOL.
As usual, you and the gang of dipshits have no clue what you’re talking about. Lmao.
Next.
Agreeing with yourself again?
This is a good point too. Part of the reason, IMO, that our prices are so high is because they are kept low by legislation in European countries and such.
Put another way, the U.S. subsidizes R&D for other parts of the world.
It’s definitely a balancing act though - the companies shouldn’t be price gouging patients but they also need to be able to recoup development costs.
So narcoleptic and BPH. At this rate, you gonna be in bad shape by end of week.
Oh I agree with that for sure. I think $1, maybe $1.50 or so is doable, eventually, with the current share structure.
I guess I meant more along the lines of before they even try to uplist with an RS. Feel like we need to see a few of these massive ANDAs get approved and selling for a bit to get a better idea of what’s possible as an acquisition price.
You think they get acquired prior to NASDAQ?
Get that prostate checked.
Did you care about it at .03 and under? Up quite a few pennies since then.
Yup. Buying another facility is not an off-the-cuff decision either. They clearly see the growth coming down the line. He first talked about needing to expand what, 6 months ago or so?
Kirko playing for keeps.
So instead of worldwide conspiracy keeping the price depressed, I should believe all the “benevolent guardian angels” on this board, like you, that say the company is crap and I should just sell all my shares?
Maybe the former is true and maybe it isn’t. I know for a fact the latter is false so I’ll take my chances. Thanks.
Oof sad, low effort
Enlarged prostate?
The irony of saying Nasrat can’t speak English after a post like that.
Almost hieroglyphics level of readability.
SEC filing out - Barry Dash exercising a warrant or something to acquire 547,657 shares?
“get rich”
As Antonio Banderas says in that old Zorro movie - “..I like that part.”
Pretty big deal for the company and I would assume is a material event - surely they PR something about it either in Dec or Jan?
Totally agree. I’m glad we have relatively low debt compared to most in our industry. We just saw how easily too much debt can suddenly sink a company like Lannett, even with more revenues than we have.
As much as I hate dilution, it’s probably better that things played out the way they did than us suffocating under a mountain of debt we can’t pay back.
No company or CEO does it perfectly but I think we’ve landed in a good place so far.
Elite getting the other half of Adderrall is the absolute fastest way to increase profits, right? We don’t want to stop the R&D train from rolling but also, Adderrall has already made it all the way through the pipe. Need to capitalize on it now while the getting is good.
Agree, BUT, also think about this. I think it’s been at least 2 quarterly filings now where they’ve said they don’t even plan to take the optional second year extensions on either the Nasrat credit line or the Caskey credit line (believe it was both). So, therefore, taking that and our current position into account - revenues, profits, Burel on Jan 1, we *shouldn’t* have any more significant dilution going forward, right?
That logic checks out, IMO. Hopefully a cash deal and not any more shares.
“The only things the company has now that it didn't back then is 3x outstanding shares and generic Adderall”
Lol yeah, stupid take.
That and oh I don’t know, 40-50+ million annually in revenues and growing, profitable, sales and marketing, and several larger ANDAs than Adderrall in multiple stages of the pipeline, on verge of a 2nd facility for packaging and storage...
You’ve had some reasonable takes before but now you just sound like a scorned ex girlfriend ready to slash tires.
Believe you’re correct JJ. Something about backup mfg machines as well. Dont have the transcript in front of me.
Cheers. Finally coming out of the aimless wandering in the desert phase. Next few years should be bright AF, need some shades.
Sad, sad existence!
Thing of beauty.
Lol .0269 - .17 52w range, wild
Zzz the guy that agrees with himself
The 20% gain from yesterday? Yeah it was awful.
Lmao who are these chumps, not even trying anymore. Put some effort into it!!
The funny part is that the CEO just laid out the roadmap for the company’s future growth. They are growing so fast that it’s actually becoming a problem to store all the finished product. Anyone with a pair of functioning eyes can clearly see the improving financials and the handful of billion dollar generic drugs they are formulating for, trialing, and have already filed for.
If people still want to sell off shares in spite of all that, their loss - just scoop up more.
I think he meant Concerta or whatever the 3rd big “needle mover” product we’ll likely file in 2024 after Oxy and Vyvanse.
Looks like replay is up - https://elite.irpass.com/events_presentations
if it hasn’t been posted here yet
Sure you got the right stock?
Same, ready to hear replay.
Geez lol
Poison pill expires as of today or tomorrow, yeah? Don’t have the old filing in front of me.
Not gonna work, clown!
Let’s goooo. So maybe just good ole fashioned FDA foot dragging.
Yup. Nasrat’s planning and Lannett’s push ironically put us in the best position yet.
IF numbers like $14.2M in revenues are a new baseline for Elite, that’s $56.8M annually.
This is also before Burel partnership starts on Jan 1.